BioArctic AB (publ) (BRCTF PINK) stock market data APIs
$29.4627
0(0%)
as of September 12, 2025
Try our APIs with
free plan!
BioArctic AB (publ) Financial Data Overview
Price chart is built with
Anychart
BioArctic AB (publ) develops biological drugs for patients with central nervous system disorders in Sweden. It engages in the research and development of innovative biological drugs, such as antibodies that address high unmet medical needs. The company's therapeutic areas encompass neurodegenerative disorders, such as Alzheimer's disease, Parkinson's disease, and other CNS diseases. In addition, it owns a technology platform, which develops a range of therapeutic monoclonal antibodies. Additionally, the company is developing lecanemab, which is in phase 3 clinical trials; Lecanemab that is in back-up phase 3 clinical trials; Exidavnemab, which is in phase 2 clinical trials; Lecanemab, BAN2803, and BAN2802 that are in preclinical trials; and BAN1503, PD-BT2238, ND-BT3814, and GD-BT6822, which are in discovery stage. It has research collaboration agreements with Eisai and AbbVie. The company was formerly known as BioArctic Neuroscience AB and changed its name to BioArctic AB (publ) in 2016. BioArctic AB (publ) was incorporated in 2000 and is based in Stockholm, Sweden.
Prev. Close
29.4627
Open
29.4627
High
29.4627
Low
29.4627
52 wk Range
12.9435-36.83
Market Cap
2 620 M
P/E Ratio
23.0697
Shares Outstanding
74 238 K
Revenue
1 860 M
EPS
0.1129
Beta
-0.697
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get BioArctic AB (publ) data using free add-ons & libraries
Get BioArctic AB (publ) Fundamental Data
BioArctic AB (publ) Fundamental data includes:
- Net Revenue: 1 860 M
- EBITDA: 1 301 M
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-28
- EPS/Forecast: 1.54
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
BioArctic AB (publ) News
New
FDA Approves BioArctic (OM:BIOA B) Lecanemab Injection For Alzheimer's
BioArctic has seen a significant price movement of 41% over the past quarter. This surge is closely tied to several positive developments, including an impressive earnings report where the company pos...
BioArctic: Gunilla Osswald awarded Uppsala University Alumnus of the year 2025
STOCKHOLM, Sept. 9, 2025 /PRNewswire/ -- Uppsala University announced today that BioArctic AB's(publ) (NASDAQ STOCKHOLM: BIOA B) CEO, Gunilla Osswald, has been awarded the title Alumnus of the Year 20...
BioArctic's founders intend to divest minor part of their shareholding
STOCKHOLM, Sept. 3, 2025 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA-B) has been made aware that the company's two founders and main shareholders, Lars Lannfelt and Pär Gellerfors, in...
Rolling sBLA initiated to the U.S. FDA for Leqembi® Iqlik™ (lecanemab-irmb) as a subcutaneous starting dose for the treatment of early Alzheimer's disease under Fast Track status
STOCKHOLM, Sept. 3, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that they have initiated a rolling submission of the Supplemental Biologics Lice...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
